Cancer risk scuppers Kyowa Kirin's autoimmune disease drug Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

#KyowaKirin has terminated all clinical trials of its anti-OX40L antibody #rocatinlimab, after cases of #cancer were seen in patients taking the drug.

pharmaphorum.com/news/cancer-...

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis - PMLiVE The phase 3 study included around 2,600 patients

#Amgen #KyowaKirin #rocatinlimab #atopicdermatitis #phase3study #ASCENDstudy #Tcellrebalancingtherapy #OX40receptor #drugsafety #efficacy #ROCKETtrial #primaryendpoint #secondaryendpoints #HORIZONtrial #IGNITEtrial #rocatinlimabmonotherapy #OX40inhibition
pmlive.com/pharma_news/...

Amgen and Kyowa Kirin Reveal Promising Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis The ASCEND study shows the potential of rocatinlimab as a long-term treatment for adults with moderate to severe atopic dermatitis, paving the way for innovative therapies.

Amgen and Kyowa Kirin Reveal Promising Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis #USA #Amgen #Thousand_Oaks #Kyowa_Kirin #Rocatinlimab

Kyowa Kirin to Present Important Findings on Rocatinlimab at EADV 2025 Congress Kyowa Kirin is set to present the Phase 3 trial results of Rocatinlimab, a promising therapy for atopic dermatitis, at the EADV congress in Paris.

Kyowa Kirin to Present Important Findings on Rocatinlimab at EADV 2025 Congress #Japan #Tokyo #Atopic_Dermatitis #Kyowa_Kirin #Rocatinlimab

Kyowa Kirin to Present Groundbreaking Findings on Rocatinlimab at EADV 2025 Kyowa Kirin Co., Ltd. is set to unveil results from the Phase 3 ROCKET IGNITE trial of rocatinlimab targeting atopic dermatitis at EADV 2025 in Paris.

Kyowa Kirin to Present Groundbreaking Findings on Rocatinlimab at EADV 2025 #Japan #Tokyo #Kyowa_Kirin #Rocatinlimab #EADV_2025

Amgen and Kyowa Kirin Announce Promising Results for Rocatinlimab in Treating Atopic Dermatitis Amgen and Kyowa Kirin revealed exciting findings from the Phase 3 IGNITE study regarding their treatment for atopic dermatitis, showcasing significant improvements.

Amgen and Kyowa Kirin Announce Promising Results for Rocatinlimab in Treating Atopic Dermatitis #USA #Amgen #Thousand_Oaks #Kyowa_Kirin #Rocatinlimab

Kyowa Kirin to Present Groundbreaking Findings from ROCKET HORIZON at AAD 2025 Kyowa Kirin recently announced the presentation of significant findings from the ROCKET HORIZON trial of rocatinlimab during the AAD 2025 conference.

Kyowa Kirin to Present Groundbreaking Findings from ROCKET HORIZON at AAD 2025 #Japan #Princeton #Kyowa_Kirin #Rocatinlimab #AAD_2025